Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Original Article

SGLT2 inhibitors and nephritis and cardiorenal outcomes in patients with systemic lupus erythematosus

Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus.

JAMA Network Open

Citation & Authors

JAMA Netw Open. 2024;7(6):e2416578.

Fu-Shun Yen; Shiow-Ing Wang; Chih-Cheng Hsu; Chii-Min Hwu; James Cheng-Chung Wei

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

importance

Lupus nephritis is a major complication of systemic lupus erythematosus (SLE). Randomized clinical trials have shown kidney and cardiac protective effects of SGLT2 inhibitors.

purpose

To investigate whether SGLT2 inhibitor use is associated with the development or progression of lupus nephritis and other cardiorenal outcomes in patients with SLE and type 2 diabetes.

Design, site and participants

This multicenter cohort study used the US Collaborative Network of the TriNetX clinical data platform to identify patients with SLE and type 2 diabetes between January 1, 2015, and December 31, 2022. Data collection and analysis took place in September 2023.

exposed

Patients were divided into SGLT2 inhibitor users and nonusers and matched 1:1 using propensity scores.

Main outcomes and measures

Kaplan–Meier methods and Cox proportional hazards regression were used to calculate adjusted hazard ratios (AHRs) for lupus nephritis, dialysis, kidney transplantation, heart failure, and death within 5 years in the two groups.

result

Among 31,790 eligible patients, propensity score matching selected 1,775 pairs of users and nonusers, totaling 3,550 patients. After matching, the mean age was 56.8 years (SD 11.6), and 3,012 patients (84.8%) were women. Compared with nonusers, users had significantly lower risks of lupus nephritis (AHR 0.55; 95% CI 0.40–0.77), dialysis (0.29; 0.17–0.48), kidney transplantation (0.14; 0.03–0.62), heart failure (0.65; 0.53–0.78), and all-cause mortality (0.35; 0.26–0.47).

Conclusion and significance

In this cohort with SLE and type 2 diabetes, SGLT2 inhibitor users had significantly lower risks of lupus nephritis, dialysis, kidney transplantation, heart failure, and all-cause mortality, suggesting possible cardiorenal protection.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.